Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

About this update from Exicure, Inc.

[{"type":"text","content":"\n\nBrian C. Bock to resign as President and CEO and become Special Advisor to the CEO for a transition period\n\n\nDr. Matthias Schroff appointed President and CEO; will replace Mr. Bock on Board of Directors\n\n\nTimothy P. Walbert, Bosun Hau, and Andrew Sassine to resign from the Board of Directors for other commitments\n\n\nDr. Elizabeth (Betsy) Garofalo appointed Chair of the Board of Directors to succeed Timothy P. Walbert\n\n\n CHICAGO--(BUSINESS WIRE)--\nExicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Brian C. Bock has submitted his resignation as President and Chief Executive Officer and a member of the Board of Directors of Exicure to pursue a new opportunity. Effective today, Mr. Bock will transition into an advisory role with the Company and will serve as Special Advisor to the Chief Executive Officer to assist during a transition period.\n\nThe Board has appointed Matthias Schroff, Ph.D., Exicure’s current Chief Scientific Officer, to succeed Mr. Bock effective February 4, 2022. Additionally, Dr. Schroff was appointed as a member of the Company’s Board of Directors to fill the vacancy resulting from Mr. Bock’s resignation from the Board.\n\nThe Company also announced today that Andrew (Andy) Sassine, a Board member and a member of the Audit Committee, has tendered his resignation to step down from the Board as of February 3, 2022. Timothy P. Walbert, who currently serves as Exicure’s Chair of the Board, and Bosun Hau, a Board member and Compensation Committee Chair, have each tendered their resignations to step down from the Board, effective February 4, 2022.\n\nThe Board has appointed Betsy Garofalo, M.D. to succeed Mr. Walbert as Chair of the Board and to serve on the Compensation Committee of the Board of Directors to fill the vacancy on the Compensation Committee resulting from Mr. Hau’s resignation from the Board. The Board also appointed Jeffrey L. Cleland, Ph.D. to serve as the Chair of the Compensation Committee following Mr. Hau’s resignation, and appointed Bali Muralidhar, M.D., Ph.D. to serve as a member of the Audit Committee following Mr. Sassine’s resignation.\n\n“On behalf of the Board and the Exicure organization, I would like to thank Brian, Tim, Bosun and Andy for all of their contributions to the Company and...

More updates from Exicure, Inc.